摘要
美国生物医药产业研发实力在全球医药产业界仍然居于绝对优势地位,连续多年R&D投资持续高速增长,为新药创新活动提供了强大的技术支撑;但是深入分析其新药类型,可以发现:美国生物医药产业研发创新仍呈明显的"渐进式创新"特征,其产业整体上选择了渐进式创新和研发外包的创新模式;研发外包(Outsourcing)以及研发业务离岸外包(Offshore Outsourcing)是当今美国生物医药产业R&D活动最重要的运行模式和发展趋势。
Investment on R＆D activities of America＇ s pharmaceutical and biotechnology has consistently increased for many years. The R＆D strength of America is still keep its predominance in the world and has paved a solid technology foundation for the innovation activities. By analysing the finial result of the innovation activities deeply, we will find the main character of America＇ s pharmaceutical and biotechnology industry displays as increment innovation, and the overall America＇ s pharmaceutical and biotechnology industries choose the increment innovation path and outsourcing model for their R＆D activities. Outsourcing as well as Offshore Outsourcing have become the most important R＆D operation model for today＇ s America pharmaceutical and biotechnology industry.
出处
《全球科技经济瞭望》
2009年第2期51-54,共4页
Global Science，Technology and Economy Outlook
关键词
生物医药产业
R&D
研发外包
渐进式创新
pharmaceutical and biotechnology industry
R＆D
outsourcing
increment innovation
